CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Cinnamomum zeylanicum +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04023539
NCT04023539N/ACompleted

Evaluation of the Effect of Cinnamomum Zeylanicum on Glycemic Levels of Mexican Adult Patients With Type 2 Diabetes at 3 Months: Randomized Clinical Trial

Universidad de Sonora·interventional·Posted Jul 17, 2019·Updated May 28, 2020

In Brief

A clinical study evaluating Cinnamomum zeylanicum and Placebo for Type 2 Diabetes. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

Type 2 Diabetes (T2D) is protected against chronic hyperglycemia. This is one of the main causes of death in the country, being a public health problem worldwide. Some studies have shown that herbal products have beneficial effects in patients with diabetes by improving the metabolism of glucose and lipids. Cinnamomum Zeylanicum (C.Z.), colloquially cinnamon, is one of the components of the diet that has active biological substances with insulin mimetic properties. In Mexico, little has been investigated about the use of this therapy. Previous studies do not conclude if there is a statistically significant effect in the glycemic control of patients with diabetes. Therefore, it is proposed to evaluate the effect of the supplement consumption of C.Z. 3 months compared to a control group on the change in glycated hemoglobin (HbA1c) in Mexican adults with T2D. This is a randomized, single-blind clinical trial with T2D patients from the clinic CAAPS . Those that are divided into: intervention group with supplement of 2g daily C.Z. Oral route (capsules) for 90 days, and control group with placebo. The figures will be recorded: HbA1c, fasting plasma glucose, blood pressure, cholesterol, HDL, LDL, triglycerides, waist circumference, weight and body mass index.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 17, 2019
Enrollment StartSep 4, 2019
Primary CompletionMar 20, 2020
Study CompletionApr 23, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.0 years ago

Interventions

Cinnamomum zeylanicumdietary

Capsules of 2 g cinnamomum zeylanicum orally

Placeboother

Placebo capsules